NASDAQ:CALA Calithera Biosciences (CALA) Stock Price, News & Analysis $0.0001 0.00 (-66.67%) As of 11:21 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitors About Calithera Biosciences Stock (NASDAQ:CALA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Calithera Biosciences alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.0001▼$0.0010Volume163 shsAverage Volume720 shsMarket Capitalization$386.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Calithera Biosciences, Inc. was a clinical-stage biotechnology company focused on developing therapies for cancer and other serious diseases by targeting cellular metabolism and the tumor microenvironment. The company was headquartered in South San Francisco, California, and its research programs were aimed at disrupting metabolic pathways that cancer cells use to grow and resist treatment. Its lead investigational product was telaglenastat (CB-839), an oral inhibitor of glutaminase, an enzyme involved in glutamine metabolism. Calithera evaluated telaglenastat in combination with other cancer treatments across several tumor types. The company also developed earlier-stage programs targeting immunosuppressive mechanisms in the tumor microenvironment, including arginase inhibition. Calithera was founded in 2010 and operated as a biotechnology company serving the global oncology research and development market through clinical collaborations and drug-development programs. In 2022, after failing to secure additional financing or strategic alternatives, the company announced plans to wind down operations and pursued bankruptcy proceedings. As a result, Calithera is no longer operating as an active publicly traded biotechnology company.AI Generated. May Contain Errors. Read More Receive CALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CALA Stock News HeadlinesCalithera Biosciences Inc (CALA)November 23, 2024 | investing.comPrimecap Management Portfolio Exposed: Top Holdings RevealedApril 26, 2024 | msn.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 1 at 1:00 AM | Chaikin Analytics (Ad)Christina CalaAugust 12, 2023 | npr.orgNCalithera Biosciences cancels special meeting due to lack of quorumJune 29, 2023 | seekingalpha.comCALA - Calithera Biosciences, Inc.May 31, 2023 | finance.yahoo.comCalithera Biosciences, Inc.: Calithera Biosciences Announces Update on Complete Liquidation and DissolutionMay 20, 2023 | finanznachrichten.deCala MarioluMay 19, 2023 | travel.usnews.comSee More Headlines CALA Stock Analysis - Frequently Asked Questions How have CALA shares performed this year? Calithera Biosciences' stock was trading at $0.0001 at the start of the year. Since then, CALA stock has increased by 0.0% and is now trading at $0.0001. How were Calithera Biosciences' earnings last quarter? Calithera Biosciences, Inc. (NASDAQ:CALA) issued its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($3.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.60) by $1.60. The biotechnology company earned $6.75 million during the quarter. When did Calithera Biosciences' stock split? Shares of Calithera Biosciences reverse split before market open on Wednesday, June 15th 2022.The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Calithera Biosciences? Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Calithera Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Dynavax Technologies (DVAX) and First Solar (FSLR). Company Calendar Last Earnings11/08/2021Today10/01/2026Next Earnings (Estimated)11/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CALA CIK1496671 Webwww.calithera.com Phone(650) 870-1000FaxN/AEmployees60Year Founded2010Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares3,860,000Free Float4,550,000Market Cap$386.00 OptionableNot Optionable Beta-1.26 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CALA) was last updated on 10/1/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calithera Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calithera Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
